Skip to content
DataLookout
Menu

HECTORNCT05068674

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 2028 to Oct 2029
    • Eligibility criteria shortened, about 2 words
  2. Notable Primary and study completion dates: Oct 2025 to Oct 2028v6
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2022 to Mar 22, 2022
    v3
  4. Minor Start date: Jan 2022 to Mar 2022
    • Collaborators expanded, about 6 words
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The maximum tolerated dose (MTD) among 3 dose levels of allogeneic human embryonic stem cell-derived cardiomyocytes (hESC-CMs)
Timeframe: 3 Years

Arms and interventions

Cohort 1Active comparator

Low dose (50M cells)

Cohort 2Active comparator

Medium dose (150M cells)

Cohort 3Active comparator

High dose (300M cells)

Drugs: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells, Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells, Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells

Sites

1 site in 1 country

  • Stanford Hospital and ClinicsPalo Alto, California, United States